Cardiff Oncology Inc Asset Resilience Ratio
Cardiff Oncology Inc asset resilience ratio. Cardiff Oncology Inc (CRDF) has an Asset Resilience Ratio of 65.98% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Cardiff Oncology Inc fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Cardiff Oncology Inc (2016–2025)
Asset resilience ratio of Cardiff Oncology Inc from 2016 to 2025. This chart shows how Cardiff Oncology Inc's Asset Resilience Ratio has changed over time. Read Cardiff Oncology Inc total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Cardiff Oncology Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Cardiff Oncology Inc asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $40.83 Million | 65.98% |
| Total Liquid Assets | $40.83 Million | 65.98% |
Asset Resilience Insights
- Very High Liquidity: Cardiff Oncology Inc maintains exceptional liquid asset reserves at 65.98% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Cardiff Oncology Inc Industry Peers by Asset Resilience Ratio
Compare Cardiff Oncology Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Cardiff Oncology Inc Asset Resilience Ratio by Year (2016–2025)
Cardiff Oncology Inc asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Cardiff Oncology Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 65.98% | $40.83 Million | $61.88 Million | +24.54pp |
| 2024-12-31 | 41.44% | $40.28 Million | $97.19 Million | -23.69pp |
| 2023-12-31 | 65.13% | $53.17 Million | $81.64 Million | -11.40pp |
| 2022-12-31 | 76.53% | $88.92 Million | $116.19 Million | -9.65pp |
| 2021-12-31 | 86.18% | $128.88 Million | $149.54 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $134.73 Million | -- |
| 2016-12-31 | 54.56% | $23.98 Million | $43.95 Million | -- |
About Cardiff Oncology Inc
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in… Read more